首頁 > 市場調查報告書 > 製藥

癌症

腫瘤藥物市場規模、佔有率和成長分析（按藥物類別、治療方法、適應症、劑型、通路和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897903

腫瘤藥物市場規模、佔有率和成長分析（按藥物類別、治療方法、適應症、劑型、通路和地區分類）－2026-2033年產業預測

Oncology Drugs Market Size, Share, and Growth Analysis, By Drug Class (Cytotoxic Drugs, Targeted Drugs), By Therapy (Chemotherapy, Targeted Therapy), By Indication, By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，腫瘤藥物市場規模將達到 1,500.8 億美元，到 2025 年將達到 1,685.4 億美元，到 2033 年將達到 4,263.2 億美元，預測期（2026-2033 年）的複合年成長率為 12.3%。

全球癌症治療市場受到人口老化、生活方式改變和環境因素導致的癌症負擔日益加重的顯著影響，因此亟需創新的治療策略。針對各種癌症持續進行研發，並滿足尚未滿足的醫療需求，對於服務不斷成長的患者群體至關重要。分子生物學、基因組學和免疫療法的進步正在改善癌症治療，尤其是透過精準醫療，靶向特定的基因突變。然而，這些藥物研發高成本，涉及廣泛的臨床前研究、臨床試驗和監管核准，可能會限制其應用。儘管存在這些障礙，但精準醫療的整合以及技術創新正為市場成長提供巨大機遇，並為腫瘤領域更有效、更安全的藥物製劑鋪平道路。

腫瘤藥物市場促進因素

全球腫瘤藥物市場正經歷顯著成長，其主要驅動力是全球癌症病例的不斷增加。人口老化、生活方式的改變以及環境條件的變化等多種因素導致了癌症發生率的上升。隨著癌症患者人數的持續成長，迫切需要開發並廣泛應用有效的腫瘤治療方法。這種日益成長的需求不僅推動了市場發展，也促進了該領域的創新，從而不斷改進治療方案，以期提高患者的治療效果和存活率。

癌症藥物市場的限制

癌症治療市場發展面臨的主要障礙之一是患者獲得創新治療方法的機會有限。醫療保健系統和可用資源的差異，尤其是在發展中和低度開發地區，阻礙了最先進治療的廣泛應用。此外，保險覆蓋範圍和報銷政策的差異進一步限制了患者的治療機會，最終影響這些重要治療方法的可及性。應對這些挑戰對於改善腫瘤治療至關重要，因為缺乏新型療法會阻礙整體市場成長和患者療效。

腫瘤藥物市場趨勢

在基因譜分析和生物標記識別技術的進步推動下，癌症藥物市場正經歷著向個人化醫療的重大轉變。這一趨勢促進了針對個別患者需求量身定做治療方案的開發，從而在提高療效的同時最大限度地減少併發症。隨著醫療機構和製藥公司積極採用這些標靶治療，患者的治療效果正在改善，傳統的「一刀切」治療方法正逐漸被取代。這種對個人化癌症治療的關注不僅推動了藥物研發的創新，也激發了投資者的興趣和需求，最終將改變癌症治療格局，並以更先進的方式改善患者照護。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen（US）
Novartis AG（Switzerland）
Bristol-Myers Squibb Company（US）
Pfizer Inc.（US）
Astellas Pharma Inc.（Japan）
Johnson & Johnson（US）
AstraZeneca plc（UK）
AbbVie Inc.（US）
Merck & Co., Inc.（US）
Eli Lilly and Company（US）
Sanofi SA（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Incyte Corporation（US）
Vertex Pharmaceuticals Incorporated（US）
Seagen Inc.（US）
Blueprint Medicines Corporation（US）
Mirati Therapeutics, Inc.（US）
Xencor, Inc.（US）
NantKwest, Inc.（US）
Zymeworks Inc.（Canada）
Karyopharm Therapeutics Inc.（US）
Exelixis, Inc.（US）

簡介目錄

Product Code: SQMIG35J2087

Oncology Drugs Market size was valued at USD 150.08 Billion in 2024 and is poised to grow from USD 168.54 Billion in 2025 to USD 426.32 Billion by 2033, growing at a CAGR of 12.3% during the forecast period (2026-2033).

The global oncology drugs market is significantly influenced by the rising cancer burden driven by an aging population, evolving lifestyles, and environmental factors, necessitating innovative treatment strategies. Continuous research and development in various cancers, alongside unmet medical needs, are crucial to catering to a growing patient base. Advances in molecular biology, genomics, and immunotherapy are enhancing cancer therapeutics, particularly through precision medicine that targets specific genetic mutations. However, the high costs of developing these drugs, due to extensive preclinical research, clinical trials, and regulatory approvals, may limit their accessibility. Despite these hurdles, the integration of precision medicine, fueled by technological innovations, presents substantial opportunities for market growth, paving the way for more effective and safer drug formulations in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Oncology Drugs Market Segments Analysis

Global Oncology Drugs Market is segmented by Drug Class, Therapy, Indication, end user and region. Based on Drug Class, the market is segmented into Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others. Based on Therapy, the market is segmented into Chemotherapy, Targeted Therapy, andImmunotherapy. Based on Indication, the market is segmented into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others. Based on Dosage Form, the market is segmented into automotive, consumer electronics, healthcare, agriculture, manufacturing, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Oncology Drugs Market

The global oncology drugs market is experiencing significant growth primarily driven by the rising prevalence of cancer cases across the globe. Several factors contribute to this escalating incidence, including an aging population, evolving lifestyle choices, and shifts in environmental conditions. As the number of individuals affected by cancer continues to rise, there is an urgent demand for the development and accessibility of effective oncology treatments. This growing need not only propels the market forward but also fosters innovation within the field, leading to the continuous advancement of therapeutic options aimed at improving patient outcomes and survival rates.

Restraints in the Oncology Drugs Market

One significant barrier to the advancement of the oncology drugs market is the restricted access to innovative therapies for patients. Disparities in healthcare systems and available resources, particularly in developing and underdeveloped regions, can impede the distribution of state-of-the-art treatment options. Additionally, variations in insurance coverage and reimbursement practices further limit patient access, ultimately impacting the uptake of these crucial therapies. This lack of accessibility to novel treatments can hinder overall market growth and patient outcomes, making it essential to address these challenges for the betterment of oncology care.

Market Trends of the Oncology Drugs Market

The oncology drugs market is witnessing a significant shift towards personalized medicine, driven by advancements in genetic profiling and biomarker identification. This trend is fostering the development of customized therapies tailored to individual patient needs, enhancing treatment efficacy while minimizing complications. As healthcare providers and pharmaceutical companies increasingly adopt these targeted approaches, patients are experiencing improved outcomes, displacing traditional one-size-fits-all treatments. This focus on personalized oncology not only fuels innovation in drug development but also boosts investor interest and demand, ultimately transforming the landscape of cancer treatment and improving patient care in a more sophisticated manner.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Oncology Drugs Market by Drug Class

Market Overview
Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
Targeted Drugs
- Monoclonal Antibodies
- Others
Hormonal Drugs
Others

Oncology Drugs Market by Therapy

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy

Oncology Drugs Market by Indication

Market Overview
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Others

Oncology Drugs Market by Dosage Form

Market Overview
Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled Syringes
- Others

Oncology Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Oncology Drugs Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seagen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blueprint Medicines Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mirati Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karyopharm Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments